Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Watson Oxytrol Launch Focus On Heavy Sampling Has Delayed Rx Uptake

Executive Summary

Watson's launch for its Oxytrol overactive bladder patch is relying on heavy sampling, the company said during its second quarter investor call Aug. 5

You may also be interested in...

Oxytrol Medicaid Reimbursement Expected In 75% Of States At Launch

Watson expects almost three-quarters of state Medicaid plans to cover its Oxytrol overactive bladder patch immediately upon launch in May

Watson Oxytrol Dry Mouth Profile Gives Overactive Bladder Patch Marketing Edge

Watson's Oxytrol dry mouth side effect profile gives the overactive bladder patch a marketing edge over oral anticholinergic agents

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts